UroGen Pharma Ltd. (LON:0XOD)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 1.08B +177.3% |
| Revenue (ttm) | 106.40M +52.9% |
| Net Income | -100.89M |
| EPS | -2.07 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 161 |
| Average Volume | 1,149 |
| Open | 30.00 |
| Previous Close | 29.89 |
| Day's Range | 28.64 - 30.00 |
| 52-Week Range | 3.61 - 32.10 |
| Beta | 1.59 |
| RSI | 65.41 |
| Earnings Date | May 6, 2026 |
About UroGen Pharma
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocal... [Read more]
Financial Performance
In 2025, UroGen Pharma's revenue was $109.79 million, an increase of 21.45% compared to the previous year's $90.40 million. Losses were -$153.49 million, 21.0% more than in 2024.
Financial numbers in USD Financial StatementsNews
UroGen Pharma Transcript: Bank of America Global Healthcare Conference 2026
ZUSDURI's rapid adoption and strong Q1 revenue were driven by improved reimbursement and positive physician experiences, with durable efficacy shown in long-term trial data. Pipeline assets like UGN-103 and UGN-501 are advancing, and upcoming conference events will highlight new clinical results.
UroGen Pharma presents 36-month ENVISION trial data
UroGen Pharma (URGN) announced a 36-month duration of response of 64.5% by Kaplan-Meier estimate in patients who achieved a complete response at three months in the pivotal Phase 3 ENVISION…
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
64.5% Probability of Remaining Event-Free at Three Years by Kaplan-Meier Analysis After Achieving Complete Response at Three Months First and Only FDA-Approved Medicine for Recurrent Low-Grade Interme...
UroGen Pharma assumed with a Buy at Ladenburg
Ladenburg assumed coverage of UroGen Pharma (URGN) with a Buy rating and $43 price target The firm says the strong early commercial adoption of Zusduri provides a “significantly de-risking path…
UroGen Pharma price target raised to $45 from $40 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on UroGen Pharma (URGN) to $45 from $40 and keeps a Buy rating on the shares. The firm views the…
UroGen Pharma price target raised to $40 from $34 at Oppenheimer
Oppenheimer raised the firm’s price target on UroGen Pharma (URGN) to $40 from $34 and keeps an Outperform rating on the shares. Zusduri’s Q1 sales of $29.2M vs. the firm/consensus…
UroGen Pharma to Present at Upcoming Investor Conferences
PRINCETON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
UroGen Pharma reports Q1 EPS (47c), consensus (36c)
Reports Q1 revenue $50.96M, consensus $55.71M. “2026 is off to a strong start, with expanding usage of ZUSDURI for intravesical solution and clear acceleration across key commercial indicators, includ...
UroGen Pharma Earnings Call Transcript: Q1 2026
Q1 2026 revenue surged 152% year-over-year to $51 million, led by ZUSDURI's rapid launch and strong prescriber growth. JELMYTO maintained stable demand, and the company expects continued ZUSDURI expansion, especially in community practices, with a solid cash position supporting ongoing growth.
UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights
ZUSDURI™ generated revenue of $29.2 million in Q1 2026, representing 109% quarter-over-quarter growth, reflecting broader utilization with the permanent J Code effective January 1, 2026 JELMYTO achiev...
UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026
Conference Call and Webcast Scheduled for Wednesday, May 6th, 2026, at 10:00 AM ET Conference Call and Webcast Scheduled for Wednesday, May 6th, 2026, at 10:00 AM ET
UroGen Pharma initiated with a Buy at Jefferies
Jefferies analyst Amin Makarem initiated coverage of UroGen Pharma (URGN) with a Buy rating and $40 price target The firm says the company’s Zusduri has “strong” Phase 3 efficacy and…
UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer
PRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
UroGen Pharma publishes results from ENVISION trial of Zusduri
UroGen Pharma (URGN) announced the publication of results from the pivotal Phase 3 ENVISION trial of Zusduri for intravesical solution in The Journal of Urology. Zusduri is indicated for the…
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
72.2% Probability of Remaining Event-Free at 24 Months by Kaplan-Meier Analysis After Achieving Complete Response at Three Months (79.6%) PRINCETON, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- UroGen Pha...
UroGen Pharma ‘commends’ BCAN release of Bladder Cancer Report
UroGen Pharma (URGN) “commended” the Bladder Cancer Advocacy Network, BCAN, on its release of The New Faces of Bladder Cancer Report. The survey found that nearly 80% of respondents reported…
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
UroGen Pharma Transcript: TD Cowen 46th Annual Health Care Conference
Strong Q4 results and a permanent J-code have accelerated adoption and revenue, with ZUSDURI now outpacing JELMYTO in key metrics. Debt refinancing enhances flexibility for R&D, while pipeline assets like UGN-103 and UGN-501 are advancing toward major milestones.
UroGen Pharma Earnings Call Transcript: Q4 2025
ZUSDURI's launch drove a 21% revenue increase in 2025, with accelerated adoption after a permanent J-code and strong pipeline progress. Financial flexibility improved with a $250 million refinancing, while JELMYTO continued steady growth.
UroGen Pharma reports Q4 EPS (54c), consensus (51c)
Reports Q4 revenue $37.837M, consensus $39.92M. “2025 was a tremendously successful and transformative year for UroGen, highlighted by the FDA approval and commercial launch of ZUSDURI, the first and ...
UroGen Pharma sees FY26 net sales for Jelmyto $97M-$101M
Guidance for full-year 2026 net product sales for Jelmyto are expected to be in the range of $97 million to $101 million. This implies a year-over-year growth rate of approximately…
UroGen Pharma announces refinanced term loan agreement with Pharmakon
UroGen Pharma (URGN) entered into an agreement with funds managed by Pharmakon Advisors to revise the terms of its loan agreement entered into in March 2024. On February 26, the…
UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results
Commercial launch is on-track for ZUSDURI™, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC); net sales...
UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors
Opportunistic refinancing meaningfully reduces cost of capital with 8.25% fixed interest rate and extends amortization period to Q1 2030
UroGen Pharma announces post-hoc analyses from Phase 3 trial of Zusduri
UroGen Pharma (URGN) announced new post-hoc analyses from the Phase 3 ENVISION trial showing that Zusduri for intravesical solution achieved durable complete response rates across European Organizatio...